Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Leukemia. 2019 Mar 26;33(10):2429–2441. doi: 10.1038/s41375-019-0454-4

Figure 4. GSK-3β inhibition increases sensitivity to chemotherapy in Burkitt lymphoma PDX.

Figure 4.

A) PDX MAP-GR-C95-BL-1 cells were treated with CHIR99021 as indicated. Western blotting was performed for β-catenin and Myc. B) PDX MAP-GR-C95-BL-1 cells were treated with DMSO or 3 μM CHIR99021 and increasing concentrations of doxorubicin for 72 hours. Cell survival was assessed as in Fig. 1B. C) ATHYM-Foxn1nu/nu mice bearing MAP-GR-C95-BL-1 xenografts were intraperitoneally injected with 8 mg/kg doxorubicin or 100 mg/kg CHIR99021 + 8 mg/kg doxorubicin. Tumors were harvested after 24 hours for immunohistochemistry (IHC). Representative images of whole tumors stained for cleaved caspase-3.